General Proximity is at the forefront of developing next-generation proximity medicines, which aim to revolutionize the field of medicine by leveraging the concept of proximity in biological processes. The company has created a generalized, mechanism-agnostic proximity discovery engine that focuses on the interactions between effector proteins—molecular machines that regulate biological functions. By understanding and manipulating the proximity events between target and effector proteins, General Proximity seeks to enable precise control over various biological outcomes, such as activation, modulation, and degradation of proteins. This innovative approach allows for the development of highly effective therapeutics, particularly for targets that have traditionally been considered "undruggable."

The company's strategy is rooted in the idea that proximity is a master regulator of biology, influencing all biological processes at some level. General Proximity's unbiased effector discovery platform is designed to identify the most potent proximity mechanisms for specific targets, thereby facilitating the creation of therapeutics that can address complex biological challenges. Collaborating with esteemed institutions and backed by significant investments, General Proximity is positioned to make substantial contributions to the field of medicine, with a focus on unlocking the potential of the effectome—the complete set of proteins that modulate biological functions.

United States

General Proximity is a seed stage biotechnology platform company founded in 2019 to pioneer the next generation of induced proximity medicines for undruggable targets. Investors include Y Combinator, Felicis, age1, Wilson Sonsini, and Modi Ventures. General Proximity is headquartered in San Francisco, California.

General Proximity

Company Details